Morgan Stanley analyst Matthew Harrison maintains Seagen (NASDAQ:SGEN) with a Overweight and lowers the price target from $181 to $170.
DermTech Announces Contracts With Highmark For The Foundational Assay Of Its DermTech Melanoma Test
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. (Highmark). The contracts, which
